Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Nephrology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
J Am Soc Nephrol. 2021 Nov;32(11):2759-2776. doi: 10.1681/ASN.2021040460.
Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease, is regulated by different forms of cell death, including apoptosis and autophagy. However, the role in ADPKD of ferroptosis, a recently discovered form of cell death mediated by iron and lipid metabolism, remains elusive.
To determine a pathophysiologic role of ferroptosis in ADPKD, we investigated whether the absence of (encoding polycystin-1) affected the expression of key factors involved in the process of ferroptosis, using Western blot and qRT-PCR analysis in mutant renal cells and tissues. We also examined whether treatment with erastin, a ferroptosis inducer, and ferrostain-1, a ferroptosis inhibitor, affected cyst growth in mutant mouse models.
We found that kidney cells and tissues lacking exhibit extensive metabolic abnormalities, including reduced expression of the system Xc amino acid antiporter (critical for import of cystine), of iron exporter (ferroportin), and of GPX4 (a key and negative regulator of ferroptosis). The abnormalities also include increased expression of iron importers (TfR1, DMT1) and HO-1, which in turn result in high iron levels, low GSH and GPX4 activity, increased lipid peroxidation, and propensity to ferroptosis. We further found that erastin increased, and ferrostatin-1 inhibited ferroptotic cell death and proliferation of -deficient cells in kidneys from mutant mice. A lipid peroxidation product increased in -deficient cells, 4HNE, promoted the proliferation of survived mutant cells activation of Akt, S6, Stat3, and Rb during the ferroptotic process, contributing to cyst growth.
These findings indicate that ferroptosis contributes to ADPKD progression and management of ferroptosis may be a novel strategy for ADPKD treatment.
常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾脏疾病,受多种形式的细胞死亡调控,包括细胞凋亡和自噬。然而,铁和脂质代谢介导的一种新发现的细胞死亡形式——铁死亡在 ADPKD 中的作用仍不清楚。
为了确定铁死亡在 ADPKD 中的病理生理作用,我们通过 Western blot 和 qRT-PCR 分析,在 突变的肾细胞和组织中研究了缺乏 (编码多囊蛋白-1)是否会影响铁死亡过程中关键因子的表达。我们还研究了用铁死亡诱导剂 erastin 和铁死亡抑制剂 ferrostain-1 处理是否会影响 突变的小鼠模型中的囊肿生长。
我们发现缺乏 的肾脏细胞和组织表现出广泛的代谢异常,包括系统 Xc 氨基酸转运体(胱氨酸摄取所必需)、铁输出蛋白(铁蛋白)和 GPX4(铁死亡的关键负调控因子)表达减少。异常还包括铁摄取蛋白(转铁蛋白受体 1、DMT1)和 HO-1 表达增加,进而导致铁水平升高、GSH 和 GPX4 活性降低、脂质过氧化增加和铁死亡倾向。我们进一步发现,erastin 增加,ferrostatin-1 抑制 突变的小鼠肾脏中 缺陷细胞的铁死亡和增殖。在 缺陷细胞中增加的脂质过氧化产物 4HNE,通过激活 Akt、S6、Stat3 和 Rb,促进存活的 突变细胞的增殖,在铁死亡过程中促进囊肿生长。
这些发现表明铁死亡促进 ADPKD 的进展,铁死亡的管理可能是 ADPKD 治疗的一种新策略。